{"entity":{"id":"nct05579132","kind":"trial","name":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)","aka":[],"tldr":"A phase 1/2 trial of MK-1045 in acute lymphoblastic leukaemia, run by MSD R&D (China) Co., Ltd., now recruiting.","summary":"A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002) is a phase 1/2 interventional study registered as NCT05579132 by MSD R&D (China) Co., Ltd., with 203 participants planned, started 2022-11-01 and due to reach its primary completion in 2028-12-31. Interventions recorded: MK-1045.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05579132","url":"https://clinicaltrials.gov/study/NCT05579132"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["mk-1045"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05579132","phase":"1/2","setting":"An Open-label, Multi-center Phase Ib/II Study of MK-1045 (CN201) in Subjects With Precursor B-cell Acute Lymphoblastic Leukemia","sponsor":"MSD R&D (China) Co., Ltd.","enrolled":203,"outcomes":[]},"route":"/trials/nct05579132/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"mk-1045","kind":"drug","name":"MK-1045","route":"/drugs/mk-1045/"}]}}